- CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
- Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³
Key statistics
As of last trade CSL Ltd (CSLLY:QXE) traded at 91.49, -12.96% below its 52-week high of 105.11, set on Jun 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 90.87 |
---|---|
High | 91.69 |
Low | 90.00 |
Bid | -- |
Offer | -- |
Previous close | 91.19 |
Average volume | 56.40k |
---|---|
Shares outstanding | -- |
Free float | -- |
P/E (TTM) | -- |
Market cap | -- |
EPS (TTM) | -- |
Annual div (ADY) | 1.18 USD |
---|---|
Annual div yield (ADY) | 1.30% |
Div ex-date | Mar 11 2024 |
Div pay-date | Apr 10 2024 |
Data delayed at least 15 minutes, as of May 06 2024 19:11 BST.
More ▼